ORTX
NASDAQOrchard Therapeutics plc
Latest news
25 items- PROrchard Therapeutics Announces Multiple Presentations at ASGCT 2024TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel (formerly OTL-200 which was recently approved as Lenmeldy™ in the
- PROrchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListTOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been named to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world's most influential individuals in health this year. The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/. "I am incredibly humbled, privileged, and immensely proud to b
- PROrchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyFive specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements are being offered to both private and government insurers to ensure broad, expedient and sustainable reimbursed access TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the de
- PROrchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.TOKYO and LONDON and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the U.S. Food and Drug Administration (FDA) has approved Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD). "The FDA approval of Lenmeldy opens up tremendous new possibilities for children in the U.S. with early-onset MLD w
- PRORI Capital Raises $260 Million for Second Life Sciences Fund- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II (the "Fund"), with total commitments of $260 million. This milestone meets the Fund's original target and underscores strong investor confidence in ORI Capital's investment strategy and track record. NATICK, Mass. Founded in 2015, and led by veteran investor, Simone Song, ORI Capital is well-positioned to identify and nurture the next generation of innovative companies. The Fund will invest in innovative early-stage biotech companies globally, across the areas of diagnostic
- 13D/GSEC Form SC 13G filed by Orchard Therapeutics plcSC 13G - Orchard Therapeutics plc (0001748907) (Subject)
- 13D/GSEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
- 13D/GSEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
- 13D/GSEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
- 13D/GSEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)
- SECSEC Form 15-12G filed by Orchard Therapeutics plc15-12G - Orchard Therapeutics plc (0001748907) (Filer)
- PROrchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeGene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S. and Europe TOKYO, LONDON and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the first patient has been randomized at the M Health Fairview Masonic Children's Hospital in a registrational trial evaluating the efficacy and safety of OTL-203, an investigational hemat
- PROrchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumBOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced 10 presentations from across its neurometabolic portfolio will be featured at the 20th Annual WORLDSymposium™ taking place February 4-9, 2024, in San Diego, California. Featured presentations include updated neurocognitive and biochemical results from an ongoing proof-of-concept study of investigational OTL-201 in mucopolysaccharidosis type IIIA (MPS-IIIA), also known as Sanfilippo syndrome type A, with median follow-up now extending to 2.75 y
- SECSEC Form EFFECT filed by Orchard Therapeutics plcEFFECT - Orchard Therapeutics plc (0001748907) (Filer)
- SECSEC Form EFFECT filed by Orchard Therapeutics plcEFFECT - Orchard Therapeutics plc (0001748907) (Filer)
- NEWSOrchard Therapeutics Reached An Agreement With The Beneluxa Initiative On Pharmaceutical Policy (Beneluxa) Enabling Reimbursed Access To Libmeldy= (atidarsagene autotemcel) Approved For The Treatment Of Early-onset Metachromatic Leukodystrophy (MLD)
- PROrchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyBOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD). The agreement covers several member countries, including Belgium, The Netherlands, and Ireland. It follows similar arrangements made with reimbursement authorities in the United Kingdom (UK), Italy, Germany, Sweden, Iceland, Finland and Norway, and is a key component of the company's
- INSIDERSEC Form 4 filed by Secor Alicia4 - Orchard Therapeutics plc (0001748907) (Issuer)
- INSIDERGeraghty James A returned 44,391 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Orchard Therapeutics plc (0001748907) (Issuer)
- INSIDERThomas Frank E returned 92,081 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Orchard Therapeutics plc (0001748907) (Issuer)
- INSIDERRowland Charles A Jr returned 12,294 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Orchard Therapeutics plc (0001748907) (Issuer)
- INSIDERBeck Joanne T. returned 9,294 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Orchard Therapeutics plc (0001748907) (Issuer)
- INSIDERDunoyer Marc returned 37,179 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Orchard Therapeutics plc (0001748907) (Issuer)
- INSIDERGaspar Bobby returned 366,158 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Orchard Therapeutics plc (0001748907) (Issuer)
- INSIDERSEC Form 4 filed by Altschuler Steven4 - Orchard Therapeutics plc (0001748907) (Issuer)
ORTX FAQ
7 questionsWhat does Orchard Therapeutics plc do?
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the...Where does ORTX stock trade?
Orchard Therapeutics plc (ORTX) is listed on NASDAQ.What sector and industry is ORTX in?
Orchard Therapeutics plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Orchard Therapeutics plc go public?
Orchard Therapeutics plc (ORTX) completed its IPO in 2018.What are analysts saying about ORTX?
Orchard Therapeutics plc has had 4 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $900.00 price target on 2021-12-29. Recent price targets range from $900.00 to $1300.00.What companies are similar to ORTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ORTX side-by-side with any of them on Quantisnow.How can I track ORTX on Quantisnow?
Quantisnow aggregates Orchard Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORTX to receive live email and push alerts on every new disclosure.